Fluoropharma Medical Inc (FPMI) 0.2600

New Post Public Reply Private Reply Replies (0) Message Board

Jul 5, 2016 at 4:22 AM

Fluoropharma Medical Inc (FPMI) 0.2600 $FPMI

FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
Marketwired - Fri Jun 17, 1:07PM CDT
MONTCLAIR, NJ--(Marketwired - June 17, 2016) - FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on recent company news and address questions from investors.

FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals
Marketwire Canada - Thu Jun 09, 11:31AM CDT
MONTCLAIR, NJ--(Marketwired - June 09, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has entered into a nonbinding letter of intent with Ground Fluor Pharmaceuticals, Inc. (GFP) to acquire GFP.
FLR: 49.24 (-0.04)

FluoroPharma Enters Development and Commercialization Agreement for China and Canada
Marketwired - Mon Jun 06, 8:51AM CDT
MONTCLAIR, NJ--(Marketwired - June 06, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma's proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.

FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific Meeting of the American Society of Nuclear Cardiology
Marketwire Canada - Wed May 25, 8:39AM CDT
MONTCLAIR, NJ--(Marketwired - May 25, 2016) - FluoroPharma Medical Inc., (OTCQB: FPMI) today announced the acceptance of the first comparative data from it's Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease (CAD). The abstract was accepted for oral presentation on September 24th, 2016 in Boca Raton, Florida.

FluoroPharma Medical Announces Details for Investor Call on January 6th
Marketwired - Tue Jan 05, 11:20AM CST
FluoroPharma Medical Inc., (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:00 p.m. EST on Wednesday, January 6, 2016. The objectives of the call are to introduce Thomas H. Tulip, Ph.D., the company's new President and Chief Executive Officer, share his vision for the company, and address questions from investors.

FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer
Marketwired - Tue Dec 29, 3:32PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today the appointment of Dr. Thomas Tulip, PhD as Chief Executive Officer.

Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves
Marketwired - Fri Oct 23, 6:52AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of cardiovascular disease, announced today the release of a company overview as presented by FluoroPharma's Chairman & CEO, Thijs Spoor, and its President, Thomas Tulip, PhD.

Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.
Marketwired - Tue Oct 06, 9:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Dr. Thomas H. Tulip will join the company as President and will be responsible for the Company's day-to-day operations, with a focus on global product and business development strategies.

FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015
Marketwired - Fri Jan 16, 4:08PM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.

FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)
Marketwired - Thu Dec 04, 10:00AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that enrollment for this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.

Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease
Marketwired - Mon Nov 03, 7:55AM CST
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced an online publication in the Journal of Nuclear Cardiology on October 25, 2014 titled "A New F-18 Labeled PET Tracer For Fatty Acid Imaging."

FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden
Marketwired - Mon Oct 20, 7:32AM CDT
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...